Skip to main content

Table 1 Demographic and Treatment Characteristics of the Participants

From: Effects of adjunct testosterone on cardiac morphology and function in advanced cancers: an ancillary analysis of a randomized controlled trial

Characteristic

All Patients

(n = 16)

Placebo

(n = 10)

Testosterone

(n = 6)

P = value

Time (mos) from diagnosis to enrollment – mean (SD)

3.1 (3.2)

2.9 (3.4)

3.6 (3.1)

0.684

Age (yrs) – mean (SD)

50.9 (9.5)

48.4 (10.9)

55.0 (5.1)

0.189

BMI (kg/m2) – mean (SD)

22.1 (6.8)

23.9 (7.3)

19.3 (5.2)

0.200

aExercise behavior (activity score) – mean (SD)

9.0 (8.0)

9.9 (9.6)

7.1 (3.6)

0.588

Race – no. (%)

   

0.330

 Non-Hispanic white

11 (69)

6 (60)

5 (83)

 

 Other group

5 (31)

4 (40)

1 (20)

 

Sex – no. (%)

   

0.091

 Male

7 (44)

6 (60)

1 (17)

 

 Female

9 (56)

4 (40)

5 (83)

 

Smoking – no. (%)

n = 16

n = 10

n = 6

0.355

 Never

4 (25)

3 (30)

1 (17)

 

 Former

7 (44)

3 (330)

4 (67)

 

 Current

5 (31)

4 (40)

1 (17)

 

Disease stage – no. (%)

n = 15

n = 9

n = 6

0.852

 IIB

1 (7)

0 (0)

1 (17)

 

 III

0 (0)

0 (0)

0 (0)

 

 IIIB

4 (27)

3 (33)

1 (17)

 

 IV

0 (0)

0 (0)

0 (0)

 

 IVA

8 (53)

5 (56)

3 (50)

 

 IVB

2 (13)

1 (11)

1 (17)

 

Cancer Type – no. (%)

   

1.000

 Cervical

6 (38)

4 (40)

2 (33)

 

 Head/neck

10 (62)

6 (60)

4 (37)

 

PEG feeding tube – no. (%)

6 (38)

3 (30)

3 (50)

0.986

Current Therapy – no. (%)

 Chemotherapy

11 (69)

6 (60)

5 (83)

0.985

 Radiotherapy

13 (81)

9 (90)

4 (67)

 

 Other Therapy

0 (0)

0 (0)

0 (0)

 

Prior therapy – no. (%)

n = 16

n = 10

n = 6

0.927

 Surgery

2 (13)

2 (20)

0 (0)

 

 Chemotherapy

0 (0)

0 (0)

0 (0)

 

 Radiotherapy

0 (0)

0 (0)

0 (0)

 

 Other Therapy

0 (0)

0 (0)

0 (0)

 

Current Medications – no. (%)

n = 16

n = 10

n = 6

0.728

 Beta-blocker

0 (0)

0 (0)

0 (0)

 

 ACE inhibitor

1 (6)

1 (10)

0 (0)

 

 ARB

1 (6)

1 (10)

0 (0)

 

 Diuretic

1 (6)

1 (10)

0 (0)

 

 Calcium channel blocker

1 (6)

1 (10)

0 (0)

 

 Aspirin

3 (19)

2 (20)

1 (17)

 

 Statin

2 (13)

2 (20)

0 (0)

 

Pre-existing conditions – no. (%)

n = 16

n = 10

n = 6

0.586

 Peripheral vascular disease

2 (13)

1 (10)

1 (17)

 

 Coronary artery disease

1 (6)

1 (10)

0 (0)

 

 Osteoporosis

1 (6)

0 (0)

1 (17)

 

 Arrhythmia

0 (0)

0 (0)

0 (0)

 

 Arthritis

0 (0)

0 (0)

0 (0)

 

 Type II diabetes

2 (13)

2 (20)

0 (0)

 

 Hyperlipidemia

2 (13)

2 (20)

0 (0)

 

 Hypertension

1 (6)

1 (10)

0 (0)

 
  1. Abbreviations: SD standard deviation, BMI body mass index, ACE angiotensin converting enzyme, ARB angiotensin II receptor blockers. aExercise behavior sum of mild, moderate, and strenuous exercise obtained from ActiGraph 3 axis accelerometry monitors available in a subset of patients (n = 8 placebo; n = 4 testosterone). No significant differences between the groups. P-values provided are from t-tests when group means were compared or chi-square tests when comparing frequency of cases between the groups
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us